Copyright Reports & Markets. All rights reserved.

Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope of Gastroesophageal Junction Adenocarcinoma Therapeutics
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Gastroesophageal Junction Adenocarcinoma Therapeutics by Type
    • 1.3.1 Overview: Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Type in 2022
    • 1.3.3 Drug
    • 1.3.4 Surgery
    • 1.3.5 Chemotherapy
    • 1.3.6 Targeted Therapy
  • 1.4 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market by Application
    • 1.4.1 Overview: Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Hospital Pharmacy
    • 1.4.3 Retail Pharmacy
    • 1.4.4 Online Pharmacy
  • 1.5 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size & Forecast
  • 1.6 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast by Region
    • 1.6.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
    • 1.6.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region, (2018-2029)
    • 1.6.3 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.4 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.5 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.6 South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Prospect (2018-2029)
    • 1.6.7 Middle East and Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Prospect (2018-2029)

2 Company Profiles

  • 2.1 Astellas Pharmaceuticals
    • 2.1.1 Astellas Pharmaceuticals Details
    • 2.1.2 Astellas Pharmaceuticals Major Business
    • 2.1.3 Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.1.4 Astellas Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Astellas Pharmaceuticals Recent Developments and Future Plans
  • 2.2 AstraZeneca
    • 2.2.1 AstraZeneca Details
    • 2.2.2 AstraZeneca Major Business
    • 2.2.3 AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.2.4 AstraZeneca Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 AstraZeneca Recent Developments and Future Plans
  • 2.3 Bayer
    • 2.3.1 Bayer Details
    • 2.3.2 Bayer Major Business
    • 2.3.3 Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.3.4 Bayer Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Bayer Recent Developments and Future Plans
  • 2.4 Beigene
    • 2.4.1 Beigene Details
    • 2.4.2 Beigene Major Business
    • 2.4.3 Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.4.4 Beigene Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Beigene Recent Developments and Future Plans
  • 2.5 Bristol-Myers Squibb
    • 2.5.1 Bristol-Myers Squibb Details
    • 2.5.2 Bristol-Myers Squibb Major Business
    • 2.5.3 Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.5.4 Bristol-Myers Squibb Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Bristol-Myers Squibb Recent Developments and Future Plans
  • 2.6 Daichii Sankyo
    • 2.6.1 Daichii Sankyo Details
    • 2.6.2 Daichii Sankyo Major Business
    • 2.6.3 Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.6.4 Daichii Sankyo Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Daichii Sankyo Recent Developments and Future Plans
  • 2.7 Elevar Therapeutics
    • 2.7.1 Elevar Therapeutics Details
    • 2.7.2 Elevar Therapeutics Major Business
    • 2.7.3 Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.7.4 Elevar Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Elevar Therapeutics Recent Developments and Future Plans
  • 2.8 Eli Lilly
    • 2.8.1 Eli Lilly Details
    • 2.8.2 Eli Lilly Major Business
    • 2.8.3 Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.8.4 Eli Lilly Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Eli Lilly Recent Developments and Future Plans
  • 2.9 FivePrime Therapeutics
    • 2.9.1 FivePrime Therapeutics Details
    • 2.9.2 FivePrime Therapeutics Major Business
    • 2.9.3 FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.9.4 FivePrime Therapeutics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 FivePrime Therapeutics Recent Developments and Future Plans
  • 2.10 Incyte
    • 2.10.1 Incyte Details
    • 2.10.2 Incyte Major Business
    • 2.10.3 Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.10.4 Incyte Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Incyte Recent Developments and Future Plans
  • 2.11 Macrogenics
    • 2.11.1 Macrogenics Details
    • 2.11.2 Macrogenics Major Business
    • 2.11.3 Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.11.4 Macrogenics Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Macrogenics Recent Developments and Future Plans
  • 2.12 Merck Co
    • 2.12.1 Merck Co Details
    • 2.12.2 Merck Co Major Business
    • 2.12.3 Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.12.4 Merck Co Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 Merck Co Recent Developments and Future Plans
  • 2.13 Ono Pharmaceuticals
    • 2.13.1 Ono Pharmaceuticals Details
    • 2.13.2 Ono Pharmaceuticals Major Business
    • 2.13.3 Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.13.4 Ono Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Ono Pharmaceuticals Recent Developments and Future Plans
  • 2.14 Roche
    • 2.14.1 Roche Details
    • 2.14.2 Roche Major Business
    • 2.14.3 Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.14.4 Roche Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 Roche Recent Developments and Future Plans
  • 2.15 Taiho Pharmaceuticals
    • 2.15.1 Taiho Pharmaceuticals Details
    • 2.15.2 Taiho Pharmaceuticals Major Business
    • 2.15.3 Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.15.4 Taiho Pharmaceuticals Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.15.5 Taiho Pharmaceuticals Recent Developments and Future Plans
  • 2.16 Zai Labs
    • 2.16.1 Zai Labs Details
    • 2.16.2 Zai Labs Major Business
    • 2.16.3 Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.16.4 Zai Labs Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.16.5 Zai Labs Recent Developments and Future Plans
  • 2.17 ZymeWorks
    • 2.17.1 ZymeWorks Details
    • 2.17.2 ZymeWorks Major Business
    • 2.17.3 ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Product and Solutions
    • 2.17.4 ZymeWorks Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
    • 2.17.5 ZymeWorks Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Revenue and Share by Players (2018-2023)
  • 3.2 Market Share Analysis (2022)
    • 3.2.1 Market Share of Gastroesophageal Junction Adenocarcinoma Therapeutics by Company Revenue
    • 3.2.2 Top 3 Gastroesophageal Junction Adenocarcinoma Therapeutics Players Market Share in 2022
    • 3.2.3 Top 6 Gastroesophageal Junction Adenocarcinoma Therapeutics Players Market Share in 2022
  • 3.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Market: Overall Company Footprint Analysis
    • 3.3.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Market: Region Footprint
    • 3.3.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Market: Company Product Type Footprint
    • 3.3.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value and Market Share by Type (2018-2023)
  • 4.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

  • 5.1 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value Market Share by Application (2018-2023)
  • 5.2 Global Gastroesophageal Junction Adenocarcinoma Therapeutics Market Forecast by Application (2024-2029)

6 North America

  • 6.1 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2029)
  • 6.2 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2029)
  • 6.3 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country
    • 6.3.1 North America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2018-2029)
    • 6.3.2 United States Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)
    • 6.3.3 Canada Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)
    • 6.3.4 Mexico Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

7 Europe

  • 7.1 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2029)
  • 7.2 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2029)
  • 7.3 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country
    • 7.3.1 Europe Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2018-2029)
    • 7.3.2 Germany Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.3 France Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.4 United Kingdom Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.5 Russia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)
    • 7.3.6 Italy Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

8 Asia-Pacific

  • 8.1 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2029)
  • 8.2 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2029)
  • 8.3 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Region
    • 8.3.1 Asia-Pacific Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Region (2018-2029)
    • 8.3.2 China Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.3 Japan Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.4 South Korea Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.5 India Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.6 Southeast Asia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)
    • 8.3.7 Australia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

9 South America

  • 9.1 South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2029)
  • 9.2 South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2029)
  • 9.3 South America Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country
    • 9.3.1 South America Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2018-2029)
    • 9.3.2 Brazil Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)
    • 9.3.3 Argentina Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

10 Middle East & Africa

  • 10.1 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Type (2018-2029)
  • 10.2 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Application (2018-2029)
  • 10.3 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size by Country
    • 10.3.1 Middle East & Africa Gastroesophageal Junction Adenocarcinoma Therapeutics Consumption Value by Country (2018-2029)
    • 10.3.2 Turkey Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)
    • 10.3.3 Saudi Arabia Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)
    • 10.3.4 UAE Gastroesophageal Junction Adenocarcinoma Therapeutics Market Size and Forecast (2018-2029)

11 Market Dynamics

  • 11.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Drivers
  • 11.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Market Restraints
  • 11.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry
  • 11.5 Influence of COVID-19 and Russia-Ukraine War
    • 11.5.1 Influence of COVID-19
    • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

  • 12.1 Gastroesophageal Junction Adenocarcinoma Therapeutics Industry Chain
  • 12.2 Gastroesophageal Junction Adenocarcinoma Therapeutics Upstream Analysis
  • 12.3 Gastroesophageal Junction Adenocarcinoma Therapeutics Midstream Analysis
  • 12.4 Gastroesophageal Junction Adenocarcinoma Therapeutics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Gastroesophageal Junction Adenocarcinoma Therapeutics market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
    Gastroesophageal Junction Adenocarcinoma (GEJAC) is a type of cancer that occurs where the esophagus meets the stomach.
    This report is a detailed and comprehensive analysis for global Gastroesophageal Junction Adenocarcinoma Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
    Key Features:
    Global Gastroesophageal Junction Adenocarcinoma Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
    Global Gastroesophageal Junction Adenocarcinoma Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
    Global Gastroesophageal Junction Adenocarcinoma Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
    Global Gastroesophageal Junction Adenocarcinoma Therapeutics market shares of main players, in revenue ($ Million), 2018-2023
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Gastroesophageal Junction Adenocarcinoma Therapeutics
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Gastroesophageal Junction Adenocarcinoma Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Astellas Pharmaceuticals, AstraZeneca, Bayer, Beigene and Bristol-Myers Squibb, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
    Market segmentation
    Gastroesophageal Junction Adenocarcinoma Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Drug
    Surgery
    Chemotherapy
    Targeted Therapy
    Market segment by Application
    Hospital Pharmacy
    Retail Pharmacy
    Online Pharmacy
    Market segment by players, this report covers
    Astellas Pharmaceuticals
    AstraZeneca
    Bayer
    Beigene
    Bristol-Myers Squibb
    Daichii Sankyo
    Elevar Therapeutics
    Eli Lilly
    FivePrime Therapeutics
    Incyte
    Macrogenics
    Merck Co
    Ono Pharmaceuticals
    Roche
    Taiho Pharmaceuticals
    Zai Labs
    ZymeWorks
    Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Gastroesophageal Junction Adenocarcinoma Therapeutics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Gastroesophageal Junction Adenocarcinoma Therapeutics, with revenue, gross margin and global market share of Gastroesophageal Junction Adenocarcinoma Therapeutics from 2018 to 2023.
    Chapter 3, the Gastroesophageal Junction Adenocarcinoma Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Gastroesophageal Junction Adenocarcinoma Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
    Chapter 12, the key raw materials and key suppliers, and industry chain of Gastroesophageal Junction Adenocarcinoma Therapeutics.
    Chapter 13, to describe Gastroesophageal Junction Adenocarcinoma Therapeutics research findings and conclusion.

    Buy now